Potential Antibiotics for the Treatment of Neonatal Sepsis Caused by Multidrug-Resistant Bacteria

• Published in: Paediatric drugs 2021-09, Vol.23 (5), p.465-484
• Main Authors: Darlow, Christopher A., da Costa, Renata M. A., Ellis, Sally, Franceschi, François, Sharland, Mike, Piddock, Laura, Das, Shampa, Hope, William
• Format: Article
• Language: English
• Subjects: Antibiotics; Antimicrobial agents; Bacteria; Bacterial infections; Dosage and administration; Drug resistance in microorganisms; Drug therapy; Enzymes; Gram-negative bacteria; Gram-positive bacteria; Internal Medicine; Medicine; Medicine & Public Health; Multidrug resistant organisms; Pediatric research; Pediatrics; Permeability; Pharmacodynamics; Pharmacokinetics; Pharmacotherapy; R&D; Research & development; Review; Review Article; Risk factors; Sepsis; Staphylococcus infections; Transfer RNA
• ISSN: 1174-5878; 1179-2019
• DOI: 10.1007/s40272-021-00465-z

Neonatal sepsis causes up to an estimated 680,000 deaths annually worldwide, predominantly in low- and middle-income countries (LMICs). A significant and growing proportion of bacteria causing neonatal sepsis are resistant to multiple antibiotics, including the World Health Organization-recommended empiric neonatal sepsis regimen of ampicillin/gentamicin. The Global Antibiotic Research and Development Partnership is aiming to develop alternative empiric antibiotic regimens that fulfil several criteria: (1) affordable in LMIC settings; (2) activity against neonatal bacterial pathogens, including extended-spectrum β-lactamase producers, gentamicin-resistant Gram-negative bacteria, and methicillin-resistant Staphylococcus aureus (MRSA); (3) a licence for neonatal use or extensive experience of use in neonates; and (4) minimal toxicities. In this review, we identify five antibiotics that fulfil these criteria: amikacin, tobramycin, fosfomycin, flomoxef, and cefepime. We describe the available characteristics of each in terms of mechanism of action, resistance mechanisms, clinical pharmacokinetics, pharmacodynamics, and toxicity profile. We also identify some knowledge gaps: (1) the neonatal pharmacokinetics of cefepime is reliant on relatively small and limited datasets, and the pharmacokinetics of flomoxef are also reliant on data from a limited demographic range and (2) for all reviewed agents, the pharmacodynamic index and target has not been definitively established for both bactericidal effect and emergence of resistance, with many assumed to have an identical index/target to similar class molecules. These five agents have the potential to be used in novel combination empiric regimens for neonatal sepsis. However, the data gaps need addressing by pharmacokinetic trials and pharmacodynamic characterisation.